oramorph 20 mg/ ml
l. molteni & c. dei f.lli alitti società di esercizio s.p.a. - morfinsulfatpentahydrat - dråper, oppløsning - 20 mg/ ml
oramorph 2 mg/ ml
l. molteni & c. dei f.lli alitti società di esercizio s.p.a. - morfinsulfatpentahydrat - mikstur, oppløsning - 2 mg/ ml
oramorph 2 mg/ ml
l. molteni & c. dei f.lli alitti società di esercizio s.p.a. - morfinsulfat - mikstur, oppløsning - 2 mg/ ml
oramorph 6 mg/ ml
l. molteni & c. dei f.lli alitti società di esercizio s.p.a. - morfinsulfat - mikstur, oppløsning - 6 mg/ ml
sixmo
l. molteni & c. dei fratelli alitti società di esercizio s.p.a. - buprenorfin hydrochloride - opioid-relaterte lidelser - andre nervesystemet narkotika - sixmo er indikert for substitusjonsbehandling for opioidavhengighet i klinisk stabil voksne pasienter som ikke krever mer enn 8 mg/dag sublingual buprenorfin, innenfor en ramme av medisinsk, sosial og psykologisk behandling.
thalidomide bms (previously thalidomide celgene)
bristol-myers squibb pharma eeig - thalidomid - multippelt myelom - immunsuppressive - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.
thalidomide lipomed
lipomed gmbh - thalidomid - multippelt myelom - immunsuppressive - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karsinom, ikke-småcellet lunge - antineoplastiske midler - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
byfavo
paion deutschland gmbh - remimazolam besilate - bevisst sedasjon - psykoleptiske - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.
lunsumio
roche registration gmbh - mosunetuzumab - lymfom, follikulært - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.